Dr. Reddy’s Laboratories has acquired tobramycin inhalation solution from Teva Pharmaceutical Industries as part of the divestiture required by the US Federal Trade Commission (FTC) before Teva could acquire Allergan’s generics business. Teva received FDA approval for itstobramycin inhalation solution in October 2013.
As part of the same process, Allergan has divested levalbuterol inhalation solution and several strengths of budesonide inhalation suspension to Impax. The levalbuterol inhalation solution was launched by Watson (Actavis) in 2012.
Actavis, which was later acquired by Allergan, launched its budesonide inhalation suspension in 0.25 and 0.5 mg vials in early 2015 and relaunched the product several months later after a court ruling invalidating an AstraZeneca patent and lifting an injunction that had stopped Actavis from marketing the product. Impax also acquired a 1 mg budesonide inhalation suspension product that has not yet been approved.
View the complete FTC Teva/Allergan divestiture table.
